Alexandria Venture Investments
Alexandria Venture Investments is a venture capital firm that develops the work in real estate technology, and healthcare sectors.
Business Model:
Revenue: $2.6B
Employees: 501-1,000
Rankings
Industries / Tags:
Detailed Alexandria Venture Investments Information
Geographic Data
Address: 26 North Euclid Avenue
City: Pasadena
State: CA
Zip: 91101
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$5B
Social
Linkedin
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Alexandria Venture Investments is a venture capital firm that develops work in real estate technology, and healthcare sectors. The company&s;s strategic venture capital platform is Alexandria Venture Investments. Since its inception in 1996, the company has invested in disruptive life science, agrifood tech, and technology companies that are developing transformative new modalities and platforms to meaningfully improve human health.
Contact Phone:
+16265780777
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 10/2021 | DNA Script | Series C | 0 |
| 3/2017 | Antiva Biosciences | Series C | 22M |
| 7/2020 | Frequency Therapeutics | Post-IPO Equity | 42.3M |
| 9/2018 | Silverback Therapeutics | Series A | 37.5M |
| 11/2018 | Ribometrix | Series A | 30M |
| 11/2022 | Cajal Neuroscience | Series A | 96M |
| 1/2018 | Skyhawk Therapeutics | Seed Round | 8M |
| 5/2021 | TwinStrand Biosciences | Series B | 50M |
| 6/2018 | Cibus | Series C | 70M |
| 6/2021 | Senda Biosciences | Series B | 0 |
| 12/2021 | Ambys Medicines | Series A | 47M |
| 4/2020 | Nitrase Therapeutics | Series A | 38M |
| 4/2019 | Insitro | Series A | 100M |
| 9/2021 | Disc Medicine | Post-IPO Equity | 0 |
| 9/2021 | Disc Medicine | Series B | 90M |
| 2/2021 | Ensoma | Series A | 0 |
| 1/2018 | Expansion Therapeutics | Series A | 55.3M |
| 9/2021 | Asher Bio | Series B | 0 |
| 3/2019 | Imara | Series B | 0 |
| 3/2019 | Prevail Therapeutics | Series B | 50M |
| 6/2021 | Mnemo Therapeutics | Series A | 90M |
| 9/2022 | Capstan Therapeutics | Series A | 102M |
| 10/2019 | Variant Bio | Series A | 24.7M |
| 9/2021 | ROME Therapeutics | Series B | 0 |
| 9/2021 | Lycia Therapeutics | Series B | 70M |
| 5/2022 | MOMA Therapeutics | Series B | 0 |
| 7/2018 | Antiva Biosciences | Series C | 15M |
| 8/2018 | Magnolia NeuroSciences | Series A | 0 |
| 4/2019 | Arrakis Therapeutics | Series B | 75M |
| 6/2021 | Veralox Therapeutics | Series A | 0 |
| 7/2018 | ORIG3N | Series B | 0 |
| 5/2023 | Myeloid Therapeutics | Series B | 0 |
| 12/2020 | Vigil Neuroscience | Series A | 50M |
| 5/2023 | Myeloid Therapeutics | Series A | 0 |
| 6/2021 | Neurona Therapeutics | Venture Round | 0 |
| 5/2021 | BioTheryX | Series E | 92M |
| 10/2020 | Dren Bio | Series A | 0 |
| 1/2021 | Blacksmith Medicines | Seed Round | - |
| 10/2017 | Ribometrix | Seed Round | 7.5M |
| 5/2021 | Soteria Biotherapeutics | Series A | 42M |
| 5/2021 | Advanced Animal Diagnostics | Series E | 0 |
| 3/2021 | StrideBio | Series B | 0 |
| 8/2022 | Senda Biosciences | Series C | 123M |
| 3/2020 | Redpin Therapeutics | Series A | 15.5M |
| 8/2021 | Sonoma BioTherapeutics | Series B | 0 |
| 1/2023 | Ensoma | Series B | 0 |
| 7/2017 | Compass Therapeutics, Inc. | Series A | - |
| 3/2018 | TCR2 | Series B | 0 |
| 2/2022 | Kallyope | Series D | 0 |
| 11/2021 | Acrivon Therapeutics | Series B | 0 |
| 1/2022 | Korro Bio | Series B | 0 |
| 1/2021 | Senti Biosciences | Series B | 105M |
| 12/2022 | Dantari | Series A | 0 |
| 2/2022 | Ventus Therapeutics | Series C | 0 |
| 12/2020 | RayzeBio | Series B | 105M |
| 6/2023 | Bitterroot Bio | Series A | 0 |
| 1/2021 | Dice Therapeutics | Series C | 80M |
| 5/2022 | Aspen Neuroscience | Series B | 0 |
| 2/2018 | Quentis | Series A | 48M |
| 12/2021 | NextVivo | Venture Round | 7.9M |
| 1/2019 | Tiburio Therapeutics | Series A | 31M |
| 3/2020 | Affinia Therapeutics | Series A | 0 |
| 12/2017 | Metacrine | Series B | 22M |
| 3/2022 | TRex Bio | Series A | 0 |
| 6/2022 | DEM BioPharma | Series A | 0 |
| 9/2018 | Benson Hill | Series C | 65M |
| 8/2021 | Effector Therapeutics | Post-IPO Equity | 0 |
| 7/2017 | Effector Therapeutics | Series C | 38.6M |
| 10/2021 | Neumora Therapeutics | Series A | 0 |
| 9/2017 | Gritstone Bio | Series B | 93M |
| 3/2022 | Celsius Therapeutics | Series B | 0 |
| 12/2019 | ImCheck Therapeutics | Series B | 53.2M |
| 2/2022 | Terray Therapeutics | Series A | 0 |
| 6/2018 | Skyhawk Therapeutics | Venture Round | 0 |
| 3/2020 | Silverback Therapeutics | Series B | 0 |
| 4/2021 | Boundless Bio | Series B | 105M |
| 4/2020 | MOMA Therapeutics | Series A | 86M |
| 5/2023 | Boundless Bio | Series C | 0 |
| 9/2018 | System1 Biosciences | Series A | 25M |
| 11/2022 | Rezo | Series A | 0 |
| 6/2019 | BlackThorn Therapeutics | Series B | 76M |
| 1/2021 | Vera Therapeutics | Series C | 0 |
| 3/2021 | Insitro | Series C | 400M |
| 2/2019 | Maze Therapeutics | Series A | 191M |
| 11/2021 | Antiva Biosciences | Series D | 0 |
| 3/2023 | Chroma Medicine | Series B | 0 |
| 11/2018 | NextCure | Series B | 93M |
| 7/2022 | Xilis | Series A | 0 |
| 6/2021 | RayzeBio | Series C | 108M |
| 7/2020 | Vesigen Therapeutics | Series A | 28.5M |
| 10/2021 | Mozart Therapeutics | Series A | 0 |
| 2/2018 | Kallyope | Series B | 66M |
| 10/2021 | Deka Biosciences | Series A | 0 |
| 2/2018 | Moderna Therapeutics | Series G | 0 |
| 9/2021 | Acrigen Biosciences | Seed Round | - |
| 12/2017 | Obsidian Therapeutics | Series A | 0 |
| 3/2018 | Prevail Therapeutics | Series A | 75M |
| 10/2019 | Adaptive Phage Therapeutics | Venture Round | 7M |
| 10/2018 | Inspirna, Inc.(formerly Rgenix, Inc.) | Series C | 40M |
| 1/2022 | Avalo | Convertible Note | 750k |
| 6/2022 | Dren Bio | Series B | 0 |
| 7/2020 | Vor Biopharma | Series B | 0 |
| 10/2018 | Stoke Therapeutics | Series B | 90M |
| 4/2021 | Alloy Therapeutics | Series C | 75M |
| 12/2021 | Meiogenix | Series A | 12.4M |
| 7/2019 | X-Vax Technology | Series A | 0 |
| 4/2021 | SeQure DX | Series A | 0 |
| 1/2021 | Myeloid Therapeutics | Series A | 50M |
| 1/2021 | Encodia | Series C | 75M |
| 1/2019 | Frequency Therapeutics | Series B | - |
| 7/2021 | Wugen | Series B | 0 |
| 9/2022 | Novome | Series B | 0 |
| 4/2017 | Arsanis | Series D | 0 |
| 9/2018 | Epic Sciences | Series E | 0 |
| 3/2018 | IDEAYA Biosciences | Series B | 0 |
| 10/2019 | Molecular Assemblies | Series A | 0 |
| 1/2019 | Immusoft | Series B | 0 |
| 5/2022 | Pleno | Seed Round | 0 |
| 3/2022 | Umaro Foods | Seed Round | 0 |
| 10/2022 | Odyssey Therapeutics | Series B | 0 |
| 1/2020 | TwinStrand Biosciences | Series A | 16M |
| 8/2021 | Humacyte | PIPE | 175M |
| 4/2022 | Pheast Therapeutics | Series A | 0 |
| 10/2021 | Immunai | Series B | 215M |
| 3/2022 | Eclipse Bioinnovations | Series A | 14M |
| 5/2021 | Inari | Series D | 0 |
| 9/2021 | LEXEO Therapeutics | Series B | 0 |
| 10/2021 | Crop Enhancement | Convertible Note | - |
| 12/2017 | Aura Biosciences | Series C | 0 |
| 6/2021 | TRex Bio | Series A | 59M |
| 1/2020 | Novome Biotechnologies | Series A | 0 |
| 5/2021 | Invaio Sciences | Series C | 88.9M |
| 3/2019 | Cardea Bio | Series A | 7.8M |
| 9/2021 | Kytopen | Series A | 0 |
| 8/2021 | Immunitas Therapeutics | Series B | 0 |
| 9/2018 | BlueLight Therapeutics | Series C | 20M |
| 9/2022 | Tavros Therapeutics | Seed Round | 7.5M |
| 9/2020 | Korro Bio | Series A | 0 |
| 5/2018 | Celsius Therapeutics | Series A | 65M |
| 4/2023 | Function Oncology | Series A | 28M |
| 11/2021 | Parthenon Therapeutics | Series A | 0 |
| 12/2019 | Aspen Neuroscience | Seed Round | 0 |
| 12/2018 | Kallyope | Series B | 21M |
| 7/2022 | Ozette Technologies | Series A | 0 |
| 8/2018 | Inari | Series B | 40M |
| 7/2022 | Cartography Biosciences | Series A | 0 |
| 6/2019 | Encoded Therapeutics | Series C | 104M |
| 11/2022 | Haystack Oncology | Series A | 56M |
| 7/2021 | Axonis Therapeutics, Inc. | Venture Round | 0 |
| 12/2020 | Faze Medicines | Series A | 81M |
| 2/2022 | Harpe Bio | Venture Round | 3M |
| 2/2022 | Harpe Bio | Convertible Note | 3.2M |
| 3/2019 | Gencove | Seed Round | 3M |
| 6/2021 | Bright Peak Therapeutics | Series B | 107M |
| 1/2021 | LEXEO Therapeutics | Series A | 0 |
| 9/2021 | Jasper Therapeutics | Post-IPO Equity | 0 |
| 7/2021 | Deep Genomics | Series C | 0 |
| 8/2021 | Thryv Therapeutics | Series A | 0 |
| 3/2017 | Boragen | Series A | 10M |
| 2/2023 | Paratus Sciences | Series A | 0 |
| 3/2017 | EGenesis | Series A | 0 |
| 7/2017 | Rodeo Therapeutics | Series A | 5.9M |
| 6/2021 | ImmuneID | Series A | 0 |
| 3/2019 | Karuna Therapeutics | Series B | 0 |
| 6/2020 | Autobahn Therapeutics | Series B | 76M |
| 4/2023 | Orbital Therapeutics | Series A | 0 |
| 3/2020 | Kallyope | Series C | 112M |
| 11/2021 | Fountain Therapeutics | Series A | 0 |
| 7/2018 | Compass Therapeutics, Inc. | Series A | 0 |
| 12/2022 | SonoThera | Series A | 0 |
| 11/2018 | Caraway Therapeutics | Series A | 23M |
| 11/2021 | Nitrase Therapeutics | Series A | 0 |
| 10/2017 | Visterra | Series C | 0 |
| 5/2018 | Insitro | Series A | 100M |
| 5/2022 | Remix Therapeutics | Series B | 0 |
| 9/2017 | LifeMine Therapeutics | Series A | 0 |
| 11/2021 | GeneCentric Therapeutics | Series B | 0 |
| 12/2019 | Jasper Therapeutics | Series A | 35M |
| 6/2018 | StrideBio | Series A | 15.7M |
| 5/2023 | Ten63 Therapeutics | Series A | 0 |
| 6/2018 | Precision BioSciences | Series B | 0 |
| 7/2017 | Evelo Biosciences | Series B | 50M |
| 10/2017 | Cydan | Venture Round | 34M |
| 9/2018 | MouSensor | Seed Round | 3.3M |
| 7/2021 | IgGenix | Series A | 0 |
| 7/2019 | GNS Healthcare | Series D | 23M |
| 9/2020 | Sonoma Pharmaceuticals | Post-IPO Equity | 70M |
| 3/2022 | Creyon Bio | Series A | 0 |
| 2/2019 | Applied Therapeutics | Series B | 0 |
| 9/2018 | OncoResponse | Series B | 40M |
| 6/2020 | Element Biosciences | Series B | 30M |
| 4/2021 | Molecular Assemblies | Series A | 0 |
| 1/2021 | AltPep | Series A | 23.1M |
| 6/2023 | AltPep | Series B | 0 |
| 10/2022 | Matchpoint Therapeutics | Series A | 70M |
| 1/2019 | Dewpoint Therapeutics | Series A | 60M |
| 4/2021 | Ventus Therapeutics | Series B | 100M |
| 10/2019 | Verseau Therapeutics | Equity | 50M |
| 1/2017 | Halio | Series C | 65M |
| 12/2020 | Remix Therapeutics | Series A | 65M |
| 11/2019 | Genetron Health | Series D | 71M |
| 4/2018 | QurAlis | Seed Round | - |
| 1/2023 | Melonfrost | Seed Round | 7M |
| 9/2018 | ENB Therapeutics | Series A | 8.1M |
| 7/2020 | Compass Therapeutics, Inc. | Venture Round | 0 |
| 5/2018 | Nohla Therapeutics | Series B | 45M |
| 2/2017 | Applied Therapeutics | Series A | 6.1M |
| 5/2021 | Marvin | Seed Round | 0 |
| 11/2017 | Codiak Biosciences | Series C | 76.5M |
| 5/2021 | miRecule | Venture Round | 0 |
| 11/2019 | miRecule | Seed Round | 0 |
| 10/2021 | IpiNovyx Bio | Seed Round | 0 |
| 2/2023 | Garuda Therapeutics | Series B | 0 |
| 10/2021 | Soli Organic | Venture Round | 0 |
| 9/2020 | Sonoma BioTherapeutics | Series A | 0 |
| 9/2019 | Boundless Bio | Series A | 46.4M |
| 3/2022 | Affini-T Therapeutics | Venture Round | 0 |
| 1/2019 | Greenlight Biosciences | Venture Round | 50M |
| 7/2022 | Ozette Technologies | Series A | 0 |
| 7/2022 | Cartography Biosciences | Series A | 0 |
| 7/2022 | Xilis | Series A | 0 |
| 6/2022 | DEM BioPharma | Series A | 0 |
| 6/2022 | Dren Bio | Series B | 0 |
| 5/2022 | Pleno | Seed Round | 0 |
| 5/2022 | Remix Therapeutics | Series B | 0 |
| 5/2022 | MOMA Therapeutics | Series B | 0 |
| 5/2022 | Aspen Neuroscience | Series B | 0 |
| 4/2022 | Pheast Therapeutics | Series A | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
